Immunotherapeutic strategies, especially those targeting the Galectin-9/Tim-3/Foxp3 interaction, may serve as the potential salvage treatments for recurrent NPC33 in recurrent NPC. The gene discussed is FOXP3; the disease is nasopharyngeal carcinoma.